Women with certain types of ovarian and breast cancers are benefiting from a relatively new class of drugs known as PARP inhibitors. Soon, men with advanced prostate cancer might be helped, too.
Clovis Oncology (CLVS) disclosed new clinical trial results Friday showing a 44 percent tumor response rate following treatment with its PARP inhibitor, called Rubraca. The median duration of response has not yet been reached.
About the Author Reprints
I signed up and paid ..
They won’t let me sign in and when I ask to reset password something sent to my e mail does not arrive..so I need help..
The reserve mail never gets to me..